Family Manage LLC Cuts Holdings in Bristol Myers Squibb Company $BMY

Family Manage LLC lowered its stake in Bristol Myers Squibb Company (NYSE:BMY) by 66.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,881 shares of the biopharmaceutical company’s stock after selling 40,598 shares during the period. Family Manage LLC’s holdings in Bristol Myers Squibb were worth $1,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in BMY. Orbimed Advisors LLC increased its stake in shares of Bristol Myers Squibb by 19.4% during the first quarter. Orbimed Advisors LLC now owns 925,000 shares of the biopharmaceutical company’s stock worth $56,101,000 after buying an additional 150,000 shares during the period. Intelligence Driven Advisers LLC raised its holdings in Bristol Myers Squibb by 18.9% in the first quarter. Intelligence Driven Advisers LLC now owns 5,205 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 829 shares in the last quarter. Gateway Wealth Partners LLC purchased a new position in Bristol Myers Squibb in the first quarter worth approximately $545,000. Quadcap Wealth Management LLC lifted its stake in Bristol Myers Squibb by 58.1% in the first quarter. Quadcap Wealth Management LLC now owns 18,578 shares of the biopharmaceutical company’s stock worth $1,127,000 after acquiring an additional 6,824 shares during the last quarter. Finally, Weiss Asset Management LP acquired a new position in Bristol Myers Squibb during the 1st quarter worth approximately $2,310,000. 76.41% of the stock is owned by institutional investors and hedge funds.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title
• Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title
• Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title
• Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title
• Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title

Bristol Myers Squibb Stock Down 0.1%

BMY stock opened at $62.05 on Monday. The stock has a market cap of $126.70 billion, a P/E ratio of 17.43, a PEG ratio of 0.18 and a beta of 0.23. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company’s 50 day moving average is $57.49 and its two-hundred day moving average is $58.06.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BMY shares. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Bank of America lowered their target price on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Guggenheim reissued a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $61.25.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.